Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2001



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Recent Advances in the Pathogenesis and Treatment of Leukemia and Lymphoma (F3)


Organizer(s) Michael W. Long and Alan M. Gewirtz
March 23—28, 2001
Keystone Resort • Keystone, Colorado USA
Abstract Deadline: Nov 22, 2000
Late Abstract Deadline:
Scholarship Deadline:
Early Registration Deadline: Jan 23, 2001

Sponsored by The Leukemia and Lymphoma Society

Summary of Meeting:
The recent convergence of research in stem cell biology, leukemic cell genetics, and drug discovery has provided remarkable insights into the pathogenesis and treatment of leukemia and lymphoma. These insights have led to the new therapeutic approaches involving the manipulation of molecular and/or biochemical pathways in leukemic cells. Nonetheless, effective treatment and cures for these blood-related diseases remains, in many cases, elusive. This symposium is designed to integrate recent knowledge regarding the basic cellular and molecular biology of leukemia and lymphoma with new approaches to diagnosis and therapy. To this end, a translation research (laboratory to bedside) approach will be encouraged throughout the meeting, with discussions covering new mechanisms regulating hematopoietic cell development, recent data from clinical trials of new molecular therapeutics, and newly emerging directions in diagnosis. The symposium will bring together basic, translational, and clinical investigators in a meeting aimed at developing potential collaborative interactions. The intention is to provide new insights into the molecular targets for the treatment of blood-related cancers.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


FRIDAY, MARCH 23

14:00—19:00
Registration

Crestone Foyer
18:15—19:15
Welcome

Crestone Foyer
19:15—19:30
Orientation

Crestone 1 - 2
19:30—20:30
Keynote Address
Meeting has ended...abstracts no longer viewable online.

Crestone 1 - 2
Owen N. Witte, HHMI/University of California, Los Angeles, USA
Lessons of the Bcr-Abl Oncogene


SATURDAY, MARCH 24

07:00—08:00
Breakfast

Castle Peaks
08:00—11:00
Hematopoietic Cytokine Signal Transduction Pathways
Meeting has ended...abstracts no longer viewable online.

Crestone 1 - 2
James N. Ihle, St. Jude Children's Research Hospital, USA
Concepts in Cytokine Signal Transduction

* Judith C. Gasson, University of California, Los Angeles, USA
Inhibition of Hematopoietic Cell Proliferation by Notch/Jagged Medicated Signaling

Warren S. Pear, University of Pennsylvania, USA
Notch Signaling in Lymphoid Cell Fate Decisions and Leukemia

Alan D. D'Andrea, Dana-Farber Cancer Institute, USA
Interaction of the Fanconi Anemia Proteins in a Common Signaling Pathway

09:20—09:40
Coffee Break

Crestone Foyer
11:00—13:00
Poster Setup

Crestone 3 - 4
16:00—18:00
Poster Session 1: Cytokine Signal Transduction Pathways/Genetic Instability/Cell Cycle Control/Transcription Factors

Crestone 3 - 4
16:30—17:30
Social Hour with Lite Bites

Crestone Foyer
20:00—21:00
Coffee Available

Crestone Foyer
20:00—22:30
Transcription Factors and Leukemogenesis
Meeting has ended...abstracts no longer viewable online.

Crestone 1 - 2
* D. Gary Gilliland, Merck & Co., Inc., USA
CBFA2 Mutations in Acquired and Inherited Leukemias

Jonathan D. Licht, Mount Sinai School of Medicine, USA
Structure and Function of the PLZF Protein of t(11;17)-APL

Daniel G. Tenen, Cancer Science Institute, Singapore
Myeloid Transcription Factors and Leukemia


SUNDAY, MARCH 25

07:00—08:00
Breakfast

Castle Peaks
08:00—11:00
Genomic Instability and Cell Cycle Control
Meeting has ended...abstracts no longer viewable online.

Crestone 1 - 2
David M. Bodine, National Institutes of Health, USA
Stem Cell Transplantation: Problems and Solutions

Thea D. Tlsty, University of California, San Francisco, USA
Loss of Genomic Integrity in Preneoplastic Cells

* Edward V. Prochownik, Children's Hospital, USA
c-Myc: New Target Genes and Functions

Richard A. Fishel, Ohio State University, USA
DNA Repair and Therapeutic Drug Resistance: New Mechanisms and New Insights

09:20—09:40
Coffee Break

Crestone Foyer
19:00—20:00
Social Hour with Lite Bites

Crestone Foyer
17:30—18:30
Late-Breaking Research
Meeting has ended...abstracts no longer viewable online.

Crestone 3 - 4
20:00—21:00
Coffee Available

Crestone Foyer
20:00—22:30
Immunotherapeutic Approaches to the Treatment of Leukemia and Lymphoma
Meeting has ended...abstracts no longer viewable online.

Crestone 1 - 2
* Irwin D. Bernstein, Fred Hutchinson Cancer Research Center, USA
Antibody Directed Therapy of Acute Myelogenous Leukemia

Curt I. Civin, University of Maryland, USA
'Armed' Hematopoietic Cells to Reduce Transplant Rejection

Ronald Levy, Stanford University, USA
Therapy of Human Lymphoma

Hyam I. Levitsky, Juno Therapeutics, USA
Integrating Cancer Vaccines into the Setting of Hematopoietic Stem Cell Transplantation


MONDAY, MARCH 26

07:00—08:00
Breakfast

Castle Peaks
08:00—11:00
New Approaches to Hematopoietic Stem Cell Homing and Transplantation
Meeting has ended...abstracts no longer viewable online.

Crestone 1 - 2
Donald Small, Johns Hopkins School of Medicine, USA
Targeting FLT3 as Specific Therapy for AML

Rainer F. Storb, Fred Hutchinson Cancer Research Center, USA
Mixed Chimerism and Graft Versus Leukemia: A Curative Concept

* Michael W. Long, University of Michigan, USA
Selectins and Their Ligands Mediated Hematopoietic Stem Cell Homing and Homeostasis

Robertson Parkman, Children's Hospital-Los Angeles, USA
Immune Reconstitution After Hematopoietic Stem Cell Transplantation

09:20—09:40
Coffee Break

Crestone Foyer
11:00—13:00
Poster Setup

Crestone 3 - 4
16:00—18:00
Poster Session 2: Novel Therapies, Purging, and Diagnostics/Pathogenesis and Therapy of AML and CML

Crestone 3 - 4
16:30—17:30
Social Hour with Lite Bites

Crestone Foyer
20:00—21:00
Coffee Available

Crestone Foyer
20:00—22:30
Modulation of Programmed Cell Death
Meeting has ended...abstracts no longer viewable online.

Crestone 1 - 2
* W. Stratford May Jr., University of Florida, USA
Novel Role for JNK as a Stress-Activated Bc12 Kinase

Craig B. Thompson, Memorial Sloan Kettering Cancer Center, USA
AKT and Bcl-x(L) Regulate Two Distinct Mechanisms That Promote Cell Survival

J. Marie Hardwick, Johns Hopkins University Schools of Public Health and Medicine, USA
Bcl-2 Family Proteins: Reversing Their Functions During Apoptosis Induced by Virus Infections and Other Death Stimuli

Louis M. Staudt, NCI, National Institutes of Health, USA
Gene Expression Profiling of Lymphoid Malignancies Reveals New Cancer Types and Mechanisms of Malignant Transformation


TUESDAY, MARCH 27

07:00—08:00
Breakfast

Castle Peaks
08:00—11:00
Novel Therapies, Purging Agents, and Diagnostics in Leukemia and Lymphoma
Meeting has ended...abstracts no longer viewable online.

Crestone 1 - 2
* Alan M. Gewirtz, University of Pennsylvania, USA
Nucleic Acid Therapeutics for Hematologic Malignancies

Kenneth C. Anderson, Dana Farber Cancer Institute, USA
New Treatment Paradigms in Multiple Myeloma

Todd R. Golub, Broad Institute, USA
Molecular Pattern Recognition in Hematologic Malignancy

Martine F. Roussel, St. Jude Children's Research Hospital, USA
The ARF/p53/Mdm2 Tumor Suppressor Pathway

09:20—09:40
Coffee Break

Crestone Foyer
16:00—17:00
Coffee Available

Crestone Foyer
16:30—18:00
Pathogenesis and Therapy of Acute and Chronic Myelogenous Leukemia
Meeting has ended...abstracts no longer viewable online.

Crestone 1 - 2
* Owen N. Witte, HHMI/University of California, Los Angeles, USA

James D. Griffin, Dana Farber Cancer Institute, USA
Mechanisms of Transformation by BCR/ABL

Brian J. Druker, Oregon Health & Science University Cancer Institute, USA
Rational Design of Therapies for Chronic Myelogenous Leukemia

Pier Paolo Pandolfi, Beth Israel Deaconess Medical Center, Harvard Medical School, USA
Demethylases and the PML/RAR Translocation in Leukemia

19:00—20:00
Social Hour

Crestone Foyer
20:00—22:00
Banquet

Castle Peaks
21:00—00:00
Entertainment

Castle Peaks

WEDNESDAY, MARCH 28

 
Departure


*Session Chair †Invited, not yet responded.



We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Yvonne Psaila, Director, Marketing and Communications, Email: yvonnep@keystonesymposia.org,
Phone:+1 970-262-2676